At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ASND Ascendis Pharma A/S
Pre-Market Trading 01-02 09:16:32 EST
137.67
+1.19
+0.87%
盘前137.67
+0.000.00%
08:00 EST
High138.00Low134.71Vol244.73K
Open138.00D1 Closing136.48Amplitude2.41%
Mkt Cap8.23BTradable Cap8.17BTotal Shares59.76M
T/O33.42MT/O Rate0.41%Tradable Shares59.32M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Analysts Offer Insights on Healthcare Companies: Pharvaris (PHVS), Ascendis Pharma (ASND) and BioNTech SE (BNTX)
TIPRANKS  ·  21:10
Analysts Offer Insights on Healthcare Companies: Pharvaris (PHVS), Ascendis Pharma (ASND) and BioNTech SE (BNTX)
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Axsome Therapeutics (AXSM) and Ascendis Pharma (ASND)
TIPRANKS  ·  2024-12-30
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Axsome Therapeutics (AXSM) and Ascendis Pharma (ASND)
Leerink Partners Keeps Their Buy Rating on Ascendis Pharma (ASND)
TIPRANKS  ·  2024-12-25
Leerink Partners Keeps Their Buy Rating on Ascendis Pharma (ASND)
Sage Therapeutics (SAGE) Surges 12.2%: Is This an Indication of Further Gains?
Zacks  ·  2024-12-23
Sage Therapeutics (SAGE) Surges 12.2%: Is This an Indication of Further Gains?
Ascendis Pharma announces commercial availability of YORVIPATH in U.S.
TIPRANKS  ·  2024-12-19
Ascendis Pharma announces commercial availability of YORVIPATH in U.S.
Ascendis Pharma a/S : Jefferies Raises Target Price to $194 From $191
THOMSON REUTERS  ·  2024-12-17
Ascendis Pharma a/S : Jefferies Raises Target Price to $194 From $191
Ascendis Pharma (ASND) Gets a Buy from Stifel Nicolaus
TIPRANKS  ·  2024-12-17
Ascendis Pharma (ASND) Gets a Buy from Stifel Nicolaus
Analysts Offer Insights on Healthcare Companies: Larimar Therapeutics (LRMR) and Ascendis Pharma (ASND)
TIPRANKS  ·  2024-12-17
Analysts Offer Insights on Healthcare Companies: Larimar Therapeutics (LRMR) and Ascendis Pharma (ASND)
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading
MT Newswires Live  ·  2024-12-17
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading
Ascendis Pharma announces results from New InsiGHTS tril of TransCon hGH
TIPRANKS  ·  2024-12-16
Ascendis Pharma announces results from New InsiGHTS tril of TransCon hGH
New InsiGHTS Trial of TransCon™ hGH (Lonapegsomatropin) in Turner Syndrome Achieved Primary Objective at Week 26
GlobeNewswire  ·  2024-12-16
New InsiGHTS Trial of TransCon™ hGH (Lonapegsomatropin) in Turner Syndrome Achieved Primary Objective at Week 26
Ascensis Pharma Says FDA Will Review Application for Adult Treatment of Growth Hormone Deficiency
Dow Jones  ·  2024-12-13
Ascensis Pharma Says FDA Will Review Application for Adult Treatment of Growth Hormone Deficiency
Ascendis Pharma's Supplemental BLA for Adult Growth Hormone Deficiency Drug Accepted by FDA
MT Newswires Live  ·  2024-12-13
Ascendis Pharma's Supplemental BLA for Adult Growth Hormone Deficiency Drug Accepted by FDA
FDA Accepts Ascendis Pharma’s Supplemental Biologics License Application for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency
GlobeNewswire  ·  2024-12-13
FDA Accepts Ascendis Pharma’s Supplemental Biologics License Application for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency
European Equities Traded in the US as American Depositary Edge Higher in Wednesday Trading
MT Newswires Live  ·  2024-12-12
European Equities Traded in the US as American Depositary Edge Higher in Wednesday Trading
Morgan Stanley Sticks to Its Hold Rating for Ascendis Pharma (ASND)
TIPRANKS  ·  2024-11-25
Morgan Stanley Sticks to Its Hold Rating for Ascendis Pharma (ASND)
European Equities Traded in the US as American Depositary Rise in Friday Trading, Up Over 1% for Week
MT Newswires Live  ·  2024-11-23
European Equities Traded in the US as American Depositary Rise in Friday Trading, Up Over 1% for Week
Ascendis Pharma a/S : Citigroup Cuts Target Price to $200 From $207
THOMSON REUTERS  ·  2024-11-18
Ascendis Pharma a/S : Citigroup Cuts Target Price to $200 From $207
Ascendis Pharma Is Maintained at Buy by TD Cowen
Dow Jones  ·  2024-11-16
Ascendis Pharma Is Maintained at Buy by TD Cowen
European Equities Traded in the US as American Depositary Drop in Friday Trading, Down 2.8% for Week
MT Newswires Live  ·  2024-11-16
European Equities Traded in the US as American Depositary Drop in Friday Trading, Down 2.8% for Week

Introduction

Company Name.
Ascendis Pharma A/S
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company also develops TransCon Growth Hormone for treating pediatric GHD, adult GHD, and turner syndrome; TransCon Parathyroid Hormone for adult patients with hypoparathyroidism; and TransCon C-type natriuretic peptide for achondroplasia. In addition, it is developing TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/? for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Issue price:
--